VivoSeq
Other

Respiratory Infections

0

Pipeline Programs

4

Active Trials

0

Companies Involved

Respiratory Infections is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

7/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

14

clinical trials

Completed7 · 50%
Active, not recruiting2 · 14%
Unknown status2 · 14%
Not yet recruiting1 · 7%
Terminated1 · 7%
Recruiting1 · 7%

Trial Activity

14 trials

OM 85 to Prevent Respiratory Infections in Older At Risk Patients
Recruiting··Phase 4·NCT06655272·360 enrolled
Role of Zinc in Recurrent Acute Lower Respiratory Infections
Completed··Phase 3·NCT00536133·208 enrolled
Comparative Effectiveness of Antibiotics for Respiratory Infections
Completed··N/A·NCT02297815·2,472 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)